Dipeptidyl Peptidase-4 Inhibitor Alarms: Is Heart Failure Caused by a Class Effect?

被引：0
|
作者：
Lee, Yong-ho [1 ]
机构：
[1] Yonsei Univ, Coll Med, Severance Hosp, Div Endocrinol & Metab,Dept Internal Med, 50-1 Yonsei Ro, Seoul 120752, South Korea
来源：
DIABETES & METABOLISM JOURNAL | 2015年 / 39卷 / 03期
关键词：
SITAGLIPTIN; RISK; DESIGN; TRIAL;
D O I：
10.4093/dmj.2015.39.3.204
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：204 / 206
页数：3
相关论文
共 50 条
  • [21] Dipeptidyl peptidase-4 inhibitors and heart failure: Risk analysis [Dipeptidyl-Peptidase-4-Hemmer und Herzinsuffizienz: Risikoanalyse]
    Vardarli I.
    Özcelik C.
    Der Kardiologe, 2014, 8 (6): : 448 - 450
  • [22] New Synthetic Route to a Dipeptidyl Peptidase-4 Inhibitor
    Lafrance, Danny
    Caron, Stephane
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2012, 16 (03) : 409 - 414
  • [23] Vildagliptin:: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties
    Ahrén, B
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2006, 15 (04) : 431 - 442
  • [24] Dipeptidyl peptidase-4 independent cardiac dysfunction links saxagliptin to heart failure
    Koyani, Chintan N.
    Kolesnik, Ewald
    Woelkart, Gerald
    Shrestha, Niroj
    Scheruebel, Susanne
    Trummer, Christopher
    Zorn-Pauly, Klaus
    Hammer, Astrid
    Lang, Petra
    Reicher, Helga
    Maechler, Heinrich
    Groschner, Klaus
    Mayer, Bernd
    Rainer, Peter P.
    Sourij, Harald
    Sattler, Wolfgang
    Malle, Ernst
    Pelzmann, Brigitte
    von Lewinski, Dirk
    BIOCHEMICAL PHARMACOLOGY, 2017, 145 : 64 - 80
  • [25] Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure
    Kankanala, Saumya Reddy
    Syed, Rafay
    Gong, Quan
    Ren, Boxu
    Rao, Xiaoquan
    Zhong, Jixin
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2016, 8 (05): : 2450 - 2458
  • [26] Effects of Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Outcomes in Patients with Heart Failure with Preserved Ejection Fraction and Diabetes
    Yamamoto, Masayoshi
    Seo, Yoshihiro
    Yamada, Yu
    Nakagawa, Taishi
    Nakatsukasa, Tomofumi
    Sugano, Akinori
    Hamada, Yoshie
    Machino, Tomoko
    Ishizu, Tomoko
    Aonuma, Kazutaka
    JOURNAL OF CARDIAC FAILURE, 2016, 22 (09) : S198 - S198
  • [27] The effect of the dipeptidyl peptidase-4 inhibitor linagliptin on proliferative retinopathy in a mouse model
    Dietrich, N.
    Schlotterer, A.
    Kern, L.
    Acunman, K.
    Klein, T.
    Hammes, H. -P.
    DIABETOLOGIA, 2016, 59 : S480 - S480
  • [28] Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials
    Kongwatcharapong, J.
    Dilokthornsakul, P.
    Nathisuwan, S.
    Phrommintikul, A.
    Chaiyakunapruk, N.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 211 : 88 - 95
  • [29] Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor
    Boulton, David W.
    CLINICAL PHARMACOKINETICS, 2017, 56 (01) : 11 - 24
  • [30] Dipeptidyl peptidase-4 inhibitor-induced bullous pemphigoid
    Reactions Weekly, 2021, 1861 (1) : 9 - 9
12345